NCT03745989View on ClinicalTrials.gov

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 22, 2019

Primary Completion Date

March 19, 2021

Study Completion Date

March 19, 2021

Conditions
Solid Tumors
Interventions
DRUG

MK-8353

Participants will receive MK-8353 orally twice daily (BID), escalated sequentially from 50 mg to 250 mg.

DRUG

Selumetinib

Participants will receive selumetinib orally BID, escalated sequentially from 25 mg to 75 mg.

Trial Locations (5)

6500

Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 0020), Bellinzona

34232

Florida Cancer Specialists ( Site 7000), Sarasota

78229

Next Oncology ( Site 0001), San Antonio

V5Z 4E6

BC Cancer-Vancouver Center ( Site 0011), Vancouver

M5G 2M9

Princess Margaret Cancer Centre ( Site 0012), Toronto

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT03745989 - Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) | Biotech Hunter | Biotech Hunter